Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase I Oncology
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
What is being tested: Novel treatment combinations pairing enfortumab vedotin with pembrolizumab, investigating whether additional agents can improve outcomes in locally advanced or metastatic…
24 Apr 2026 NCT07232602
● Recruiting Phase I Oncology
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
What is being tested: GTAEXS617 (REC-617), a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced…
23 Apr 2026 NCT05985655
● Recruiting Phase I Oncology
Study of STP938 in Advanced Solid Tumours
What is being tested: STP938 is an investigational drug being evaluated in a Phase 1 dose escalation and safety expansion study as a monotherapy…
23 Apr 2026 NCT06297525
● Recruiting Phase I Oncology
Study for AZD4360 in Participants With Advanced Solid Tumours
What is being tested: AZD4360, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced…
23 Apr 2026 NCT06921928
● Recruiting Phase I / Phase II
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
ADX-038, a new drug for rare blood disorder PNH, was tested for safety and effectiveness in healthy people and patients.
22 Apr 2026 NCT05876312
● Recruiting Phase I Neurology
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Treatment being tested: AZD0120, a dual-targeting CAR-T cell therapy designed to target both BCMA and CD19 on B cells, being evaluated for safety and…
22 Apr 2026 NCT07224373
● Recruiting Phase I Oncology
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Drug Being Tested: NDI-219216, a novel investigational agent being evaluated for safety, tolerability, and efficacy in patients with advanced solid tumours through a phased…
22 Apr 2026 NCT06898450
active not recruiting Phase I / Phase II Oncology
Durvalumab and Tremelimumab for Pediatric Malignancies
Study testing safe doses of two immunotherapy drugs in children with advanced cancers, then checking if they work.
21 Apr 2026 NCT03837899
● Recruiting Phase I Oncology
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
What is being tested: AZD3470, an investigational oral agent, is being evaluated as both a standalone treatment and in combination with other anticancer drugs…
21 Apr 2026 NCT06137144
active not recruiting Phase I / Phase II
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
BION-1301 was tested for safety and tolerability in healthy people and IgA kidney disease patients.
20 Apr 2026 NCT03945318
● Recruiting Phase I Oncology
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
What is being tested: RO7656594, a novel investigational agent, is undergoing evaluation for its safety profile, tolerability, pharmacokinetics (drug behaviour in the body), and…
20 Apr 2026 NCT05800665
● Recruiting Phase I Oncology
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
What is being tested: Divarasib, a KRAS G12C inhibitor, is being evaluated as monotherapy and in combination regimens for safety, pharmacokinetics, and anti-tumour activity…
20 Apr 2026 NCT05789082
● Recruiting Phase I Oncology
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
What is being tested: PF-08046054/SGN-PDL1V, a novel therapeutic agent, is being evaluated for safety and tolerability both as monotherapy and in combination with pembrolizumab…
20 Apr 2026 NCT05208762
● Recruiting Phase I Oncology
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
What is being tested: Combination therapies pairing bispecific antibodies (mosunetuzumab or glofitamab) with cereblon E3 ligase modulators (CELMoDs: CC-220 and/or CC-99282) to evaluate safety,…
20 Apr 2026 NCT05169515
● Recruiting Phase I Oncology
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
What is being tested: BAY3498264 combined with sotorasib in patients with advanced solid cancers carrying KRASG12C mutations, investigating whether combination therapy improves efficacy beyond…
20 Apr 2026 NCT06659341
● Recruiting Phase I Oncology
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
VIR-5500 (AMX-500) is a novel therapeutic agent undergoing evaluation for safety, pharmacokinetics, and efficacy in prostate cancer, progressing from initial dose escalation as monotherapy…
20 Apr 2026 NCT05997615
active not recruiting Phase I Oncology
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
A study testing a new oral drug (MOMA-313) in patients with advanced cancers, assessing safety, dosage, and effectiveness alone or combined.
17 Apr 2026 NCT06545942
● Recruiting Phase I
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
ALN-4285 safety, tolerability, and how the body processes single doses tested in healthy adults.
17 Apr 2026 NCT07295717
● Recruiting Phase I / Phase II
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/2 trial testing oral pirtobrutinib for immune thrombocytopenia, evaluating safety, tolerability, and effectiveness at different doses.
17 Apr 2026 NCT06721013
● Recruiting Phase I Oncology
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Treatment Being Tested: BNT314 (immunotherapy) combined with BNT327 (immune checkpoint inhibitor) and chemotherapy in a randomised, multi-site design to evaluate efficacy and safety in…
17 Apr 2026 NCT07079631
● Recruiting Phase I Oncology
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Treatment being tested: BNT323 combined with BNT327 (both investigational agents) to determine optimal dosing, safety profile, and clinical efficacy in advanced breast cancer across…
17 Apr 2026 NCT06827236
● Recruiting Phase I Oncology
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
What is being tested: BNT329, an investigational drug designed to target CA19-9-expressing advanced solid tumors, with primary focus on establishing safety profile and optimal…
17 Apr 2026 NCT07186842
● Recruiting Phase I Oncology
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
BAY 3713372 is a novel PRMT5 inhibitor being tested in a first-in-human trial to treat MTAP-deleted solid tumors, designed to selectively target cancer cells…
17 Apr 2026 NCT06914128
● Recruiting Phase I Cardiology / Cardiovascular
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Treatment Being Tested: Sonrotoclax (BGB-11417), a BCL2 inhibitor, evaluated as monotherapy and combined with established myeloma regimens (carfilzomib, daratumumab, or pomalidomide) in relapsed/refractory multiple…
16 Apr 2026 NCT04973605
● Recruiting Phase I Neurology
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
Early-stage trial testing safety and user experience of new vaginal progesterone device versus standard pessaries in women with luteal phase insufficiency.
15 Apr 2026 NCT07136922
● Recruiting Phase I Oncology
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Treatment being tested: SX-682 (a CXCR4 inhibitor) combined with apalutamide (an androgen receptor inhibitor) in men with metastatic castration-resistant prostate cancer, aiming to overcome…
15 Apr 2026 NCT07002320
● Recruiting Phase I Oncology
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
What is being tested: A dual immunotherapy combination of BNT324 (B7-H3 targeted antibody-drug conjugate) and BNT327 (PD-L1/VEGF bispecific antibody) to evaluate efficacy and safety…
15 Apr 2026 NCT06892548
● Recruiting Phase I Neurology
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Treatment being tested: ECUR-506, a novel therapeutic intervention for neonatal-onset Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder caused by defective ammonia…
15 Apr 2026 NCT06255782
● Recruiting Phase I Cardiology / Cardiovascular
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
What is being tested: BGB-16673 is a novel investigational agent being evaluated in a dose-escalation and expansion study to determine safe and effective dosing…
15 Apr 2026 NCT05006716
● Recruiting Phase I / Phase II
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Early-stage trial testing a new oral drug (nuvisertib) for safety and effectiveness in myelofibrosis patients.
14 Apr 2026 NCT04176198
● Recruiting Phase I Oncology
A Phase 1/1b Study of IAM1363 in HER2 Cancers
What is being tested: IAM1363, a novel therapeutic agent, is undergoing Phase 1/1b evaluation to assess its safety profile and preliminary efficacy in patients…
14 Apr 2026 NCT06253871
● Recruiting Phase I Oncology
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Treatment Being Tested: Gedatolisib (a PI3K/mTOR inhibitor) combined with darolutamide (an androgen receptor antagonist) in metastatic castration-resistant prostate cancer, with dose-finding and efficacy evaluation…
14 Apr 2026 NCT06190899
● Recruiting Phase I Oncology
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
What is being tested: A phase 1/2 dose-escalation study investigating the combination of two investigational drugs—Pasritamig (JNJ-78278343) and JNJ-86974680—to identify the optimal tolerated dose…
14 Apr 2026 NCT07319871
● Recruiting Phase I Oncology
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
What is being tested: (177Lu) rhPSMA-10.1 is a radioligand therapy targeting PSMA-expressing tumours in metastatic castrate-resistant prostate cancer, with evaluation of optimal dosing, safety…
14 Apr 2026 NCT05413850
● Recruiting Phase I Oncology
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
What is being tested: A Phase 1b/2 dose-escalation study evaluating the combination of two investigational agents (JNJ-78278343 and JNJ-95298177) in prostate cancer, with Part…
14 Apr 2026 NCT07082920
● Recruiting Phase I Oncology
Study of INCB123667 in Subjects With Advanced Solid Tumors
Drug Being Tested: INCB123667 is a novel investigational agent being evaluated for safety, tolerability, pharmacokinetics, and anti-tumour efficacy in advanced/metastatic solid tumours, tested both…
14 Apr 2026 NCT05238922
● Recruiting Phase I Oncology
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Treatment being tested: A combination of two novel agents—tulmimetostat (DZR123), a targeted therapy, and JSB462 (luxdegalutamide), a GLP-1 receptor agonist—evaluated against standard of care…
14 Apr 2026 NCT07206056
● Recruiting Phase I Oncology
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
BNT116 is a first-in-human immunotherapy being evaluated as monotherapy and in combination regimens for advanced non-small cell lung cancer (NSCLC), with the primary aim…
14 Apr 2026 NCT05142189
active not recruiting Phase I Oncology
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
This trial compares different formulations of niraparib and abiraterone acetate to ensure they work similarly in men with advanced prostate cancer.
13 Apr 2026 NCT04577833
● Recruiting Phase I Respiratory / COPD / Asthma
NAL ER IPF Respiratory Function and Safety Study
What is being tested: Escalating doses of NAL ER (N-acetylcysteine extended-release) to evaluate its safety, tolerability, and effects on respiratory function in idiopathic pulmonary…
10 Apr 2026 NCT07036029
● Recruiting Phase I Oncology
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
What is being tested: Neoadjuvant ipilimumab (an immune checkpoint inhibitor) administered before standard surgical treatment in newly diagnosed glioblastoma patients, evaluating both safety and…
10 Apr 2026 NCT07134842
● Recruiting Phase I Oncology
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
What is being tested: YL201 (an investigational cancer therapy) combined with atezolizumab (an immune checkpoint inhibitor) in a phase Ib/II dose escalation and expansion…
10 Apr 2026 NCT07407933
● Recruiting Phase I
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019
This study tracks how the body absorbs, breaks down and eliminates a single dose of an experimental drug called GRT6019.
09 Apr 2026 NCT07479745
● Recruiting Phase I
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
ALXN2230 single injection tested for safety and tolerability in healthy volunteers.
09 Apr 2026 NCT07352423
active not recruiting Phase I / Phase II Oncology
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
GEN1042 antibody tested alone and combined with pembrolizumab, with or without chemotherapy, in patients with solid tumours.
08 Apr 2026 NCT04083599
● Recruiting Phase I Cardiology / Cardiovascular
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
A study testing whether PET scans reliably detect amyloid buildup in hearts of patients with cardiac amyloidosis.
08 Apr 2026 NCT06790394
● Recruiting Phase I Oncology
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced…
08 Apr 2026 NCT06188520
● Recruiting Phase I Oncology
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer is Recruiting • Phase I • Oncology • NCT07181161. The…
08 Apr 2026 NCT07181161
● Recruiting Phase I Oncology
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 is Recruiting • Phase I • Oncology • NCT05570422. This is a seamless…
08 Apr 2026 NCT05570422
● Recruiting Phase I
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) is Recruiting • Phase I •…
07 Apr 2026 NCT04165486